Markus Haeberlein serves as Alkermes’ Senior Vice President of Research. In this role, Dr. Haeberlein oversees Alkermes’ research efforts in neuroscience and oncology, which includes the areas of disease biology, chemistry, protein therapeutics, molecular modeling and bioinformatics.   

Dr. Haeberlein has nearly 25 years of experience in drug discovery and development. Before joining Alkermes as Vice President of Discovery in 2015, he served as Chief Science Officer at Proteostasis Therapeutics where he was responsible for all research. Prior to joining Proteostasis Therapeutics, Dr. Haeberlein held a number of roles with increasing responsibility at AstraZeneca, including leading the Global Chemistry Network (GCN) where he was responsible for AstraZeneca’s global chemistry strategy and its implementation.  

Dr. Haeberlein earned a Master of Science in Physical Chemistry, Biochemistry and Organic Chemistry and a Ph.D. in Physical Chemistry/Computational Chemistry from the Royal Institute of Technology in Stockholm, Sweden.